Athos announces research collaboration to advance precision medicine in inflammatory bowel disease
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
This facility will design & develop instruments, perform product reliability performance testing and verification
The Drug Registry intends to create a nationally recognized source of information on various systems of medicine in the country
Fujifilm has been at the forefront of medical imaging and healthcare informatics. It’s developing new AI platforms to address medical challenges. Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India gives us an insight in an interview with Thomas C. Thottathil, Editor, indianpharmapost.com
Subscribe To Our Newsletter & Stay Updated